Brain Disease Transmitted By Tick Bites May Be Treatable

Summary: Researchers have identified specific anti-bodies that can have a neutralizing effect on the virus responsible for tick-borne encephalitis. Preliminary response in using the anti-bodies in mice has proven affected in preventing TBE. It is hoped a vaccine candidate for TBE can be developed for humans.

Source: Rockefeller University

Tick-borne encephalitis is a disease just as nasty as it sounds. Once bitten by an infected tick, some people develop flu-like symptoms that resolve quietly but leave behind rampant neurological disease–brain swelling, memory loss, and cognitive decline. Cases are on the rise in Central Europe and Russia with some 10,000 incidents reported each year. Vaccines can provide protection, but only for a limited time. There is no cure.  

Now a new study describes antibodies capable of neutralizing the virus transmitted by tick bites. These so-called broadly neutralizing antibodies have shown promise in preventing TBE in mice and could inform the development of better vaccines for humans.

Further, preliminary results suggest that the antibodies may not only prevent tick-borne encephalitis but even treat the condition, as well as the related Powassan virus emerging in the United States. 

Lead author Marianna Agudelo and colleagues in the laboratory of Rockefeller’s Michel C. Nussenzweig examined nearly 800 antibodies obtained from individuals who had recovered from TBE or had been vaccinated to prevent infection.

The most potent antibodies, designated VH3-48, turned out to be best suited to fend off future infections. They found that VH3-48 neutralized lab-grown varieties of the TBE virus, as well other tick-borne illnesses including the Langat, Louping ill, Omsk hemorrhagic fever, Kyasanur forest disease, and Powassan viruses. 

The researchers also showed that these powerful antibodies are not common; in fact, most of the antibodies produced by humans exposed to TBE virus are of inferior quality, with the coveted VH3-48 antibodies making only occasional appearances. Moreover, vaccinated patients in the study did not manage to develop any VH3-48 antibodies at all.

“You’d expect the most prevalent antibodies to be the absolute best, but that is not what we found in TBE,” Agudelo says. “This may explain how the virus tricks the immune system, misdirecting it into producing inferior antibodies.” 

This shows a castor bean tick on a blade of grass
The castor bean tick, which is prevalent throughout Europe, can cause both Lyme disease and tick-borne encephalitis. Credit: Laboratory of Molecular Immunology at The Rockefeller University

The discovery of VH3-48 provides hope for a more effective TBE vaccine. Current vaccines require three doses spaced over two years and only provide about five years of protection before a booster shot is required. Next-generation vaccines built around coaxing the body into producing the rare VH3-48 antibody could be more potent, require fewer booster shots, and also prove protective against a number of tick-borne viruses.  

“A vaccine like this would not just be more elegant, but also better focused,” says Michel C. Nussenzweig, the Zanvil A. Cohn and Ralph M. Steinman Professor and head of the Laboratory of Molecular Immunology at Rockefeller. “Now that we have the structures of these antibodies, we know what to target in order to design more effective vaccines.” 

Broadly neutralizing antibodies may also provide the first specific treatment for TBE. Nussenzweig, Agudelo, and colleagues found that mice infected with TBE recover after receiving antibody therapy, although it remains to be seen if this finding will translate to humans.

“The next step is a clinical trial with the antibodies,” Nussenzweig says, “perhaps in Europe where there are many cases, to see whether we can ameliorate the symptoms of those suffering from encephalitis.”

About this neurology research news

Source: Rockefeller University
Contact: Katherine Fenz – Rockefeller University
Image: The image is credited to Laboratory of Molecular Immunology at The Rockefeller University

Original Research: Open access.
Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease” by Michel C. Nussenzweig et al. Journal of Experimental Medicine



Abstract

Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease

Tick-borne encephalitis virus (TBEV) is an emerging human pathogen that causes potentially fatal disease with no specific treatment. Mouse monoclonal antibodies are protective against TBEV, but little is known about the human antibody response to infection.

Here, we report on the human neutralizing antibody response to TBEV in a cohort of infected and vaccinated individuals. Expanded clones of memory B cells expressed closely related anti-envelope domain III (EDIII) antibodies in both groups of volunteers.

However, the most potent neutralizing antibodies, with IC50s below 1 ng/ml, were found only in individuals who recovered from natural infection. These antibodies also neutralized other tick-borne flaviviruses, including Langat, louping ill, Omsk hemorrhagic fever, Kyasanur forest disease, and Powassan viruses.

Structural analysis revealed a conserved epitope near the lateral ridge of EDIII adjoining the EDI–EDIII hinge region. Prophylactic or early therapeutic antibody administration was effective at low doses in mice that were lethally infected with TBEV.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.
  1. I am so grateful for the information you provide. I have alot of neurological problems. I know it doesn’t have to be so hard to function it is extremely sad to know “that, if only”. Your articles give me hope for our future. I am thrilled of the new enlightenment that is happening. Thank you.

  2. Why is it impossible to subscribe to your Newsletter, always saying, subscription failed?

    1. Hi Rex,

      Some people experience issues when trying to sign up with Gmail/yahoo accounts. The email service sometimes flags free provider accounts as potential spam, and that does cause some issues for genuine subscribers when signing up. If you email us via the form on our contact page with your problem and email account you would like added, we will see to it that your account is verified and the posts fly to your inbox.

Comments are closed.